A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2011
10/27/2011	US20110262503 Flowable Wound Matrix and its Preparation and Use
10/27/2011	US20110262492 Catalyst and byproduct-free native chemical ligation using cyclic thioester precursors
10/27/2011	US20110262491 Emulsions and methods of making nanocarriers
10/27/2011	US20110262486 Bone implant and manufacturing method thereof
10/27/2011	US20110262485 Sting (stimulator of interferon genes), a regulator of innate immune responses
10/27/2011	US20110262479 Recombinant mhc molecules useful for manipulation of antigen-specific t-cells
10/27/2011	US20110262471 Rab6kifl/kif20a epitope peptide and vaccines containing the same
10/27/2011	US20110262464 Compositions, Kits, and Methods for the Diagnosis, Prognosis, and Monitoring of Cancer Using GOLPH3
10/27/2011	US20110262455 Treatment of proliferative disorders with a death receptor agonist
10/27/2011	US20110262453 Markers for Assessing the Susceptibility of Cancer to IGF-1R Treatment
10/27/2011	US20110262449 Method for the treatment of gout or pseudogout
10/27/2011	US20110262442 Compositions for treating cns disorders
10/27/2011	US20110262437 Use of erbb4 as a prognostic and therapeutic marker for melanoma
10/27/2011	US20110262432 mutated netrin 4 proteins, fragments thereof and their uses as drugs
10/27/2011	US20110262424 Recombinantly produced human factor viii and ix
10/27/2011	US20110262423 Suppression of cancer
10/27/2011	US20110262422 Orally administrable dosage forms comprising angiogenin and uses thereof
10/27/2011	US20110262421 Pharmaceutical composition, food or drink, or feed for intestinal disease
10/27/2011	US20110262420 Inhalant comprising modified superoxide dismutase
10/27/2011	US20110262419 Specifically targeted catalytic antagonists and uses thereof
10/27/2011	US20110262414 High affinity ny-eso t cell receptors
10/27/2011	US20110262413 Methods of reducing extravasation of inflammatory cells
10/27/2011	US20110262403 Method of accelerating osteogenic differentiation and composition thereof
10/27/2011	US20110262400 Probiotic bacterial molecules and their use in methods to treat/prevent infection by harmful bacteria and to provide nutritional health
10/27/2011	US20110262398 Cardiac treatment using anti-fibrotic agents
10/27/2011	US20110262397 Compounds, compositions, and methods for control of hepatitis c viral infections
10/27/2011	US20110262396 Combination treatments comprising protease binding proteins for inflammatory disorders
10/27/2011	US20110262395 Sensory receptors for chronic fatigue and pain and uses thereof
10/27/2011	US20110262393 Composition comprising mesenchymal stem cells or culture solution of mesenchymal stem cells for the prevention or treatment of neural diseases
10/27/2011	US20110262392 Medium derived from stem cells as a pharmaceutical composition
10/27/2011	US20110262391 Ca9 gene single nucleotide polymorphisms predict prognosis and treatment response of metastatic renal cell carcinoma
10/27/2011	US20110262390 Composition and method for treating inflammatory disorders
10/27/2011	US20110262389 Tumor-derived Biological Antigen Presenting Particles
10/27/2011	US20110262388 Novel inhibitors
10/27/2011	US20110262387 Methods and materials for reducing or suppressing amyloid deposition
10/27/2011	US20110262386 Methods of treating inflammation
10/27/2011	US20110262385 Use of interleukin-22 in the treatment of fatty liver disease
10/27/2011	US20110262384 Pharmaceutical Polypeptide Dry Powder Aerosol Formulation and Method of Preparation
10/27/2011	US20110262383 Naphthalimide Dosing by N-Acetyl Transferase Genotyping
10/27/2011	US20110262379 Maleamic Acid Polymer Derivatives and Their Bioconjugates
10/27/2011	US20110262366 Compounds for targeting endothelial cells, compositions containing the same and methods for their use
10/27/2011	US20110262365 Methods of diagnosing hypersensitivity to a female reproductive hormone and treating medical conditions associated with same
10/27/2011	US20110262362 Methods for treating obesity
10/27/2011	US20110262360 Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof
10/27/2011	US20110262359 Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
10/27/2011	US20110262358 Molecular marker for cancer stem cell
10/27/2011	US20110262355 Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
10/27/2011	US20110262350 Breast endothelial cell expression patterns
10/27/2011	US20110262347 Methods and compositions for enhanced delivery of compounds
10/27/2011	CA2796725A1 Uses of natriuretic peptide constructs
10/27/2011	CA2796706A1 High affinity leptins and leptin antagonists
10/27/2011	CA2796607A1 Lysosomal storage disease enzyme
10/27/2011	CA2795222A1 Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
10/26/2011	EP2380991A1 Method of determining the metastatic potential of a tumor
10/26/2011	EP2380971A2 Perivascular mesenchymal precursor cells
10/26/2011	EP2380969A2 Perivascular mesenchymal precursor cell induced blood vessel formation
10/26/2011	EP2380914A1 Fusion proteins of apoptin-protein transduction domain of carboxyl-terminal end of ec-sod
10/26/2011	EP2380905A1 Phospholipid-enriched vesicles bearing tissue factor having haemostatic activities and uses thereof
10/26/2011	EP2380904A1 G protein coupled receptor agonists and antagonists and methods of use
10/26/2011	EP2380633A1 Use of IL-21 in cancer
10/26/2011	EP2380587A1 Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
10/26/2011	EP2380586A2 Oligopeptides as coating material for medical products
10/26/2011	EP2380585A1 Methods of treating autoimmune diseases
10/26/2011	EP2380584A1 Immunostimulatory method
10/26/2011	EP2380583A1 Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
10/26/2011	EP2380582A1 Low-concentration nutritional composition
10/26/2011	EP2380581A1 Muscle-building agent
10/26/2011	EP2380435A2 Feline-derived protein and method for production thereof
10/26/2011	EP2380023A2 Oxidized cardiolipin as a novel pro-inflammatory factor
10/26/2011	EP2379720A1 Mir-21 promoter driven targeted cancer therapy
10/26/2011	EP2379593A2 Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
10/26/2011	EP2379589A2 Compounds, compositions and use
10/26/2011	EP2379587A1 Melanocortin analogs with antimicrobial activity
10/26/2011	EP2379584A1 Soluble polypeptides for use in treating autoimmune and inflammatory disorders
10/26/2011	EP2379493A1 Process for the preparation of asymmetrical bis(thiosemicarbazones)
10/26/2011	EP2379113A1 Methods of treating tumor cells using rhcc protein, fragment or variant
10/26/2011	EP2379101A1 Mutated antithrombins, a process for preparing the same and their use as drugs
10/26/2011	EP2379100A1 Method for treating hyperglycemia with glp-1
10/26/2011	EP2379099A1 Method for the prophylaxis or treatment of flushing
10/26/2011	EP2379098A1 Compositions and methods to prevent cancer with cupredoxins
10/26/2011	EP2379097A1 Compositions and methods to prevent cancer with cupredoxins
10/26/2011	EP2379096A2 Tfpi inhibitors and methods of use
10/26/2011	EP2379077A2 Pharmaceutical composition
10/26/2011	EP2379053A1 Prophylactic/therapeutic agent for cancer
10/26/2011	EP2378875A1 Cell-permeant peptide-based inhibitor of kinases
10/26/2011	EP2193200B1 Nucleic acid codifying for a utrophin transcription specific regulating protein, protein codified thereby and uses thereof
10/26/2011	EP2150561B1 Demannosylated recombinant factor VIII for the treatment of patients with haemophilia A
10/26/2011	EP2021475B1 High-affinity antagonists of elr-cxc chemokines
10/26/2011	EP1888100B1 Use of il-18bp isoforms for the treatment and/or prevention of neurological inflammatory diseases
10/26/2011	EP1879611B1 Insp163 polypeptides and polynucleotides for the treatment or prevention of lung cancer
10/26/2011	EP1864994B1 Par-2 agonist
10/26/2011	EP1742964B1 Peptide capable of altering tubulin polymerization and use thereof for inhibiting cell proliferation
10/26/2011	EP1692158B1 Vegf binding and supported peptides for treating skin diseases
10/26/2011	EP1684719B1 Alpha 1-antitrypsin compositions and treatment methods using such compositions
10/26/2011	EP1587526B1 Mntf peptides and compositions and methods of use
10/26/2011	EP1469310B1 Diagnostic for scleroderma
10/26/2011	EP1409748B1 Recombinant Adenoviruses comprising simian adenovirus proteins and uses thereof.
10/26/2011	EP1352055B1 Map kinase integrin-binding domain
10/26/2011	EP1060247B2 Ox-40 receptor binding agent for use in methods for enhancing tumour antigen-specific immune response
10/26/2011	EP0787191B2 Nucleotide sequences of hiv-1 type (or subtype) o retrovirus antigens

1 ... 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 ... 3163